^
    over1year
    Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. (PubMed, Cancer Lett)
    Both oncogenic EGFR mouse models developed multifocal LUADs from which transplantable cancer cell lines sensitive to the EGFR-specific TKIs, gefitinib and osimertinib, were derived. Importantly, osimertinib treatment significantly increased intratumoral T cell content and decreased neutrophil content relative to diluent treatment. The findings provide strong evidence supporting the requirement for adaptive immunity in the durable therapeutic control of EGFR mutant lung cancer.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • RAG1 (Recombination Activating 1)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR L860R
    |
    Tagrisso (osimertinib) • gefitinib